Valeant Beats Q3 Views, Unveils Altered Strategy

By | October 19, 2015

Scalper1 News

Embattled drug giant Valeant Pharmaceuticals (VRX) beat Q3 estimates and raised its guidance Monday, but the stock was down 5% in early trading as the CEO admitted that recent controversy over its prices is leading to new strategies, including a possible sale of its neurology business. Valeant said its cash EPS in the quarter totaled $2.74 a share, up 30% from the year-earlier quarter and beating analysts’ consensus by 4 cents, according to Scalper1 News

Scalper1 News